Company intelligence / Profile preview

NingBo Junyan Hongshi Biosciences

Ningbo, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

Junyan Hongshi Biosciences is a Chinese biotechnology company focused on the discovery and development of innovative small molecule therapeutics. The company primarily targets innate immune pathways, specifically focusing on Toll-like receptor (TLR) agonists for the treatment of oncology and infectious diseases. Their lead research efforts involve dual TLR7/8 agonists designed to enhance the body's immune response against solid tumors and chronic viral infections like Hepatitis B. Based in Ningbo, China, the firm leverages medicinal chemistry to optimize drug candidates for improved safety and efficacy profiles.

Therapeutic areas: Infectious DiseasesOncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on NingBo Junyan Hongshi Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NingBo Junyan Hongshi Biosciences.